Recent Updates
Recently added Catalysts
ATHE

SECURITIES AND EXCHANGE COMMISSION

Key Takeaway: SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2012 Prana Biotechnology Limited (Name of Registrant) Level 2, 369 Royal Parade Parkville Victor

Full Press Release Details

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2012
Prana Biotechnology Limited
(Name of Registrant)
Level 2, 369 Royal Parade Parkville
Victoria 3052 Australia
(Address of Principal
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If "Yes" is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
PRANA BIOTECHNOLOGY LIMITED
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
PRANA BIOTECHNOLOGY LIMITED
(Registrant)
By /s/ Geoffrey Kempler
Geoffrey Kempler,
Executive Chairman
Last updated: Dec 12, 2012